| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE44186 | ASTRAZENECA AB | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
Jul, 2023
(8 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6395767 | ASTRAZENECA AB | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
Feb, 2021
(3 years ago) | |
| US8628799 | ASTRAZENECA AB | Coated tablet formulation and method |
Jul, 2025
(1 year, 2 months from now) | |
| US9339472 | ASTRAZENECA AB | Coated tablet formulation and method |
Jul, 2025
(1 year, 2 months from now) | |
Kombiglyze Xr is owned by Astrazeneca Ab.
Kombiglyze Xr contains Metformin Hydrochloride; Saxagliptin Hydrochloride.
Kombiglyze Xr has a total of 4 drug patents out of which 2 drug patents have expired.
Expired drug patents of Kombiglyze Xr are:
- US6395767
- USRE44186
Kombiglyze Xr was authorised for market use on 05 November, 2010.
Kombiglyze Xr is available in tablet, extended release;oral dosage forms.
Kombiglyze Xr can be used as adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both saxagliptin and metformin is appropriate.
Drug patent challenges can be filed against Kombiglyze Xr from 31 July, 2013.
The generics of Kombiglyze Xr are possible to be released after 13 July, 2025.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-134) | May 24, 2016 |
| M(M-175) | Apr 05, 2019 |
| M(M-198) | Feb 27, 2020 |
| New Chemical Entity Exclusivity(NCE) | Jul 31, 2014 |
Drugs and Companies using METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE ingredient
NCE-1 date: 31 July, 2013
Market Authorisation Date: 05 November, 2010
Treatment: Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both saxagliptin and metformin is appropriate
Dosage: TABLET, EXTENDED RELEASE;ORAL
KOMBIGLYZE XR family patents
